Emerging data reveals that retatrutide, a novel medication, could represent a significant advance in size loss . This therapy combines the actions of a GLP-1 agonist and a GIP receptor , seemingly offering a enhanced benefit than existing therapies . Patient assessments have demonstrated promising findings , including significant reductions in bod